IN BRIEF: Physiomics Pens New Merck KGaA, Bicycle Therapeutics Deals

Physiomics PLC - oncology consultant - Says awarded further contracts of undisclosed value with ...

Alliance News 16 October, 2020 | 4:37PM
Email Form

Physiomics PLC - oncology consultant - Says awarded further contracts of undisclosed value with clients Bicycle Therapeutics PLC and Merck KGaA. "The project with Bicycle is the eighth signed with this high-profile UK biotech company, spanning four different assets within its pipeline, and involves population pharmacokinetic analysis of clinical data from one of these assets," Physiomics says.

"The project with Merck is an extension of one of the projects previously announced for calendar year 2020 in what is now the third year of work under the Master Services Agreement announced in November 2017."

Current stock price: 6.78 pence

Year-to-date change: up 97%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Physiomics PLC 7.80 GBX 6.12 -
Merck KGaA 141.10 EUR -0.11

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies